Evidence map›Paper›PMID 26464736›Full record

ReviewInternational journal of clinical and experimental pathology2015

Multifocal intraductal tubulopapillary neoplasm of the pancreas with total pancreatectomy: report of a case and review of literature.

David Kölby, Johan Thilén, Roland Andersson, Agata Sasor, Daniel Ansari

Open access · greenAbstract readCase ReportsReview
In one paragraph

Review in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 3 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Multimodality imaging studies of intraductal tubulopapillary neoplasms of the pancreas.Diagnostic and interventional radiology (Ankara, Turkey) · 2019
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. When Lightning Strikes Twice.Digestive diseases and sciences · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

David KölbyDepartment of Surgery, Clinical Sciences Lund, Lund University, Skåne University Hospital Lund, Sweden.
Johan ThilénDepartment of Surgery, Clinical Sciences Lund, Lund University, Skåne University Hospital Lund, Sweden.
Roland AnderssonDepartment of Surgery, Clinical Sciences Lund, Lund University, Skåne University Hospital Lund, Sweden.
Agata SasorDepartment of Pathology, Clinical Sciences Lund, Lund University, Skåne University Hospital Lund, Sweden.
Daniel AnsariDepartment of Surgery, Clinical Sciences Lund, Lund University, Skåne University Hospital Lund, Sweden.
Lund University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intraductal neoplasms of the pancreas are classified as intraductal tubulopapillary neoplasms (ITPNs) and intraductal papillary mucinous neoplasm (IPMNs) in the current WHO classification. ITPN is a rare tumor and there are only a few cases of ITPN reported in the literature. We present the case of an otherwise healthy 42-year-old male, who presented with upper abdominal pain. He was subsequently diagnosed with multifocal ITPN and underwent total pancreatectomy. The pathological report showed invasive growth. The postoperative course was uneventful and the patient received 6 months of adjuvant chemotherapy with gemcitabine-capecitabine. The patient is still alive 19 months after the procedure with no signs of recurrence. Literature review revealed only 30 individual cases of ITPN in the pancreas including our reported case. Mean age was 61 years (16 males/14 females; ratio 1.14:1). Mean tumor size was 3 cm. Immunohistochemical staining was positive for CK-7 in 100% of the patients, CK-19 in 95% and for MUC-1 in 88%. Trypsin was negative in all cases. β-catenin was negative in 94% and MUC-2 was negative in 96% of the cases. BRAF, KRAS, TP53 and PIK3CA mutations were infrequently seen. Invasive growth was present in 54% of the cases. Tumor size and Ki-67 index showed a statistically significant association with invasive growth. Survival rate could not be determined, due to short follow-up, and further research is needed to establish prognostic factors for disease recurrence and survival.

Indexed as

AdultAntineoplastic Combined Chemotherapy ProtocolsCapecitabineCarcinoma, PapillaryChemotherapy, AdjuvantDeoxycytidineGemcitabineHumansMalePancreatectomyPancreatic DuctsPancreatic NeoplasmsCapecitabineDeoxycytidineGemcitabineIntraductal tubulopapillary neoplasminvasive growthpancreas

Identifiers

PMID26464736
PMCPMC4583968
OpenAlexW1896857346

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.